In the ever-evolving field of pharmaceutical research and development, the integration of in silico modeling has emerged as a transformative approach, particularly in the context of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative. This groundbreaking framework seeks to assess the proarrhythmic risk of new drugs before they reach clinical trials, thereby enhancing patient...